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patients were enrolled; 45 completed the EuroQol and
SF-36. Mean preferences estimated by the Brazier and
Fryback equations were 0.815 (SD: 0.110, Range: 0.497–
0.971) and 0.655 (SD: 0.060, Range: 0.511–0.791). The
mean EuroQol score was 0.553 (SD: 0.347, Range:
0.239–1.000). The correlation coefficient between pre-
dicted preferences from Brazier and Fryback’s equations
and the EuroQol were 0.613 and 0.494, respectively. The
mean preference scores produced by the three methods
were significantly different (F  24.59, p  0.0001) and
both of the predictive equations yielded significantly
higher mean values (p  0.05) than the EuroQol. CON-
CLUSIONS: Both equations to estimate a single, prefer-
ence-based index from the SF-36 produced higher mean
scores and a narrower range of values than the EuroQol.
Preferences produced by the Brazier equation were more
highly correlated with EuroQol scores than preferences
from the Fryback equation. The Fryback equation also
produced a wider range of scores. Continued develop-
ment and validation of predictive equations is needed in
order to use SF-36 scores in cost-utility analyses.
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OBJECTIVES: The aim of this study was to evaluate in-
ter-rater and inter-modality agreement in assessing health
status using the Health Utilities Index Mark 3 (HUI3).
METHODS: A random sample from a Dutch cohort of
14-year-old Very Low Birth Weight children and their
parents were invited to participate in a HUI3 face-to-face
(n  150) or telephone interview (n  150). All 300 par-
ticipants were also sent a HUI3 questionnaire by mail.
Response rate was 68%. RESULTS: Inter-rater and inter-
modality agreement were high for the physical HUI3
attributes and poor for the psychological attributes. Chil-
dren and parents reported more dysfunction in the psy-
chological attributes when interviewed than when com-
pleting the mailed questionnaire. High agreement on the
physical attributes may have resulted from the fact that
hardly any dysfunction was reported in these attributes,
and poor agreement in the psychological attributes may
have been a result of the fact that in these attributes much
more dysfunction was reported. CONCLUSIONS: In
measuring children’s health status using the HUI3, the re-
sults and their interpretation vary with the source of in-
formation and the modality of administration. For maxi-
mum comparability between studies, written self-report
questionnaires seem the preferred option.
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OBJECTIVES: Compliance with drug treatment and
health related quality of life (HRQL) are two distinct
concepts. However, we might expect a weak positive re-
lationship between the two, i.e. higher compliance is as-
sociated with higher HRQL. The purpose of this study
was to assess the relationship between compliance and
HRQL. METHODS: HRQL was measured using the
physical (PCS) and mental (MCS) component summary
measures of the MOS Short-Form 12 (SF-12). Compli-
ance was assessed using Morisky’s instrument. Three lon-
gitudinal datasets were used to investigate the relation-
ship. One dataset (n  100) included hypertensive
patients aged between 34 and 80 years. Another dataset
(n  199) covered high risk community-dwelling individ-
uals between 27 and 93 years of age. In this dataset, 43%
reported taking medication to control blood pressure.
The third dataset (n  365) consisted of elderly patients,
of whom 57% reported taking medication for pain relief
and 47% to control blood pressure. There are two obser-
vations per patient in the first dataset and three per pa-
tient in the other two. In all datasets, patients were taking
at least one prescribed medication. Correlation coeffi-
cients established the relationship between PCS, MCS
and compliance. RESULTS: In all datasets, MCS was
positively correlated to compliance. PCS was positively
correlated to compliance in the hypertensive and the el-
derly populations and was negatively correlated to com-
pliance in the high risk population. Correlation between
compliance and PCS range from 0.00 (p  0.96) to 0.09
(p  0.03). Correlation between compliance and MCS
range from 0.01 (p  0.90) to 0.21 (p  0.00). CON-
CLUSIONS: Correlation between PCS, MCS and compli-
ance was in general positive but typically small or negligi-
ble. Further research is needed to establish the relationship
between compliance and HRQL.
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OBJECTIVES: Administrative databases are often used
to investigate patterns of health care resource use and ex-
penditure over time for particular conditions in order to
project future costs and to evaluate the cost-effectiveness
of interventions. Duration of the period of observation
typically varies across individuals due to differences in
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enrollment/disenrollment dates, timing of the index event,
and the database time span. Projecting expenditure on an
annual or per member per month basis requires standard-
izing these periods of observation. We evaluate bias in-
troduced by a simple method for annualizing utilization
and cost measures. METHODS: We investigated resource
use and costs surrounding an index event; hospital ad-
mission with a primary diagnosis of heart failure. For
each patient, claims data were available for a pre-event
and post-event period ranging from 6 to 24 months. We
standardized periods to one year pre- and post-event by
first tabulating counts and costs for the actual period ob-
served. We then multiplied these values by the ratio of
365 days to actual days in the period such that values for
periods shorter than 365 days were inflated and longer
than 365 days deflated. To determine whether this ad-
justment biased the magnitude of annualized values, we
estimated a regression model with annualized cost and
adjustment ratio as dependent and independent variables
respectively. RESULTS: For the pre-event period, there
was no significant association between annualized cost
and adjustment factor (p  0.72, R2  0.00014, p 
0.012) indicating absence of bias. While bias was ob-
served in the post-event adjustment factor (p  0.005),
the low model explanatory power (R2  0.00869) and
lack of correlation (Pearson correlation coefficient 0.093)
suggest minimal impact on the magnitude of annualized
estimates. CONCLUSION: We find that a simple approach
to standardization was reasonably robust. We compare
advantages and disadvantages with more complex regres-
sion-based methods.
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BACKGROUND: Fabry disease (FD) is a rare genetic
disorder of metabolism due to a deficiency of a lysosomal
enzyme (alpha-galactosidase A) and the resultant accu-
mulation of globotriasylceramide in the cerebrovascular
and cardiovascular systems, kidney, and liver. Symptoms
become manifest during childhood or adolescence and
progress to include episodes of extremity pains, renal fail-
ure, cardiomyopathy, and/or strokes. OBJECTIVES: To
better understand quality of life (QOL) in FD patients
relative to disease progression, and normatively, com-
pared to other chronic diseases. METHODS: Data were
collected prospectively from a sample of 85 FD patients
contacted through the Fabry Support and Information
Group. Subjects responded to a survey that included the
SF-36, a symptoms checklist, and extensive demographic
questions. Information about SF-36 performance for
other populations was collected from the literature. Data
on 53 males are reported here. RESULTS: Patients with
FD have substantially lower QOL across all domains
compared to the 25th percentile of the general male pop-
ulation, as well as that observed for patients with Gau-
cher disease, renal disease, and stroke. There is also a very
substantial decrease in QOL from early adulthood through
middle age (data not shown here). CONCLUSIONS: These
data suggest that FD places an increasing and unusually
heavy QOL burden on patients, especially related to gen-
eral health, physical role and vitality. Research is cur-
rently underway to determine whether enzyme replace-
ment therapy can alleviate this burden. (See table below.)
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Negative affectivity (NA) has been shown to be strongly
and consistently correlated to patient reported, subjective
health indicators. Therefore, subjective health indicators
may or may not give an accurate assessment of the indi-
vidual’s true health status. NA can be expected to act as a
general nuisance factor in health research, one that taps
organically spurious variance. The pervasive influence of
NA may confound the results and complicate the inter-
pretation of health related quality of life instruments,
such as the SF-36. OBJECTIVE: The purpose of this
study was to evaluate the potential influence of NA on
the MOS SF-36. METHODS: We used Structural Equa-
Table for PQP9
SF-36 Scores FD Males
General US Male Population
(25th Percentile)
Gaucher Disease
(Untreated) Stroke
Renal Disease
(Hemodialysis)
Physical Function 52 80 67 65 82
Role Physical 28 75 52 54 68
Bodily Pain 49 62 65 75 70
General Health 28 62 51 64 51
Vitality 35 50 42 55 59
Social Functioning 56 75 71 86 75
Role Emotional 53 67 64 80 75
Mental Health 63 68 65 80 69
